Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MesemCart
- Development stage
- Phase 2
- Lead developer
- BIONCaRT
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular, Implant
01
Overview
**MesemCart** is an investigational allogeneic umbilical cord tissue-derived mesenchymal stromal cell therapy developed by BIONCaRT for focal cartilage defects of the knee. The product is intended for one-time local application to the cartilage defect during minimally invasive or arthroscopic surgery, using a collagen-containing support matrix. It is being evaluated for safety, tolerability, and preliminary efficacy in regeneration of hyaline-like cartilage and improvement of symptoms associated with knee cartilage damage. ([bioncart.com](https://bioncart.com/en/))
- Brand names
- MesemCart
- Other names
- BPCC001BPCC-001BPCC 001MesemCart
Beyond the preview
Go deeper on MesemCart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MesemCart.